Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to stop cancer wasting in colorectal patients

NCT ID NCT07033026

Symptom relief Sponsor: NGM Biopharmaceuticals, Inc Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a drug called NGM120 in people with colorectal cancer who are losing weight due to cancer cachexia. The goal is to see if NGM120 can help patients gain or maintain weight and improve their quality of life. About 136 participants will receive either NGM120 or a placebo every 4 or 8 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
NGM120
What this could lead to
If it works, this could lead to a treatment that helps colorectal cancer patients with cachexia maintain or gain weight and feel better.
What could go wrong
This is an early Phase 2 trial with only 136 participants, so results may not apply to everyone. The drug may not improve weight or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 136 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Documented active diagnosis of colorectal cancer. 2. Cachexia defined by Fearon criteria of weight loss. 3. Signed informed consent. Exclusion Criteria: 1. Current active reversible causes of decreased food intake. 2. Receiving tube feedings or parenteral nutrition at the time of Screening or Randomization. 3. Have cachexia caused by other reasons.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer cachexia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal carcinoma colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer cachexia Colorectal cancer CRC (colorectal cancer)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    27 sites in 4 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • NGM Clinical Study Site

    RECRUITING

    Los Angeles, California, 90033, United States

  • NGM Clinical Study Site

    RECRUITING

    Los Angeles, California, 90095, United States

  • NGM Clinical Study Site

    RECRUITING

    Santa Rosa, California, 95403, United States

  • NGM Clinical Study Site

    RECRUITING

    Margate, Florida, 33063, United States

  • NGM Clinical Study Site

    RECRUITING

    Baltimore, Maryland, 21201, United States

  • NGM Clinical Study Site

    RECRUITING

    New York, New York, 10065, United States

  • NGM Clinical Study Site

    RECRUITING

    Toledo, Ohio, 43608, United States

  • NGM Clinical Study Site

    RECRUITING

    Youngstown, Ohio, 44504, United States

  • NGM Clinical Study Site

    RECRUITING

    Dallas, Texas, 75390, United States

  • NGM Clinical Study Site

    WITHDRAWN

    Kingwood, Texas, 77339, United States

  • NGM Clinical Study Site

    RECRUITING

    Laredo, Texas, 78041, United States

  • NGM Clinical Study Site

    RECRUITING

    Richmond, Virginia, 23114, United States

  • NGM Clinical Study Site

    RECRUITING

    Appleton, Wisconsin, 54915, United States

  • NGM Clinical Study Site

    RECRUITING

    Tbilisi, 159, Georgia

  • NGM Clinical Study Site

    RECRUITING

    Tbilisi, 159, Georgia

  • NGM Clinical Study Site

    RECRUITING

    Tbilisi, 159, Georgia

  • NGM Clinical Study Site

    RECRUITING

    Tbilisi, 159, Georgia

  • NGM Clinical Study Site

    RECRUITING

    Tbilisi, 186, Georgia

  • NGM Clinical Study Site

    RECRUITING

    Goyang, 10326, South Korea

  • NGM Clinical Study Site

    RECRUITING

    Goyang, 1048, South Korea

  • NGM Clinical Study Site

    RECRUITING

    Incheon, 21565, South Korea

  • NGM Clinical Study Site

    RECRUITING

    Seoul, 2841, South Korea

  • NGM Clinical Study Site

    RECRUITING

    Seoul, 3080, South Korea

  • NGM Clinical Study Site

    RECRUITING

    Seoul, 6351, South Korea

  • NGM Clinical Study Site

    RECRUITING

    Suwon, 16247, South Korea

  • NGM Clinical Study Site

    RECRUITING

    Taichung, 407216, Taiwan

  • NGM Clinical Study Site

    RECRUITING

    Taipei, 100225, Taiwan

  • NGM Clinical Study Site

    RECRUITING

    Taoyuan, 333423, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.